ES2325865T3 - Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos. - Google Patents

Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos. Download PDF

Info

Publication number
ES2325865T3
ES2325865T3 ES05773290T ES05773290T ES2325865T3 ES 2325865 T3 ES2325865 T3 ES 2325865T3 ES 05773290 T ES05773290 T ES 05773290T ES 05773290 T ES05773290 T ES 05773290T ES 2325865 T3 ES2325865 T3 ES 2325865T3
Authority
ES
Spain
Prior art keywords
methyl
ethyl
pyrrolidin
oxazol
phenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES05773290T
Other languages
English (en)
Spanish (es)
Inventor
Lisa Selsam Beavers
Serge Louis Boulet
Terry Patrick Finn
Robert Alan Gadski
William Joseph Hornback
Cynthia Darshini Jesudason
Richard Todd Pickard
Freddie Craig Stevens
Grant Matthews Vaught
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Application granted granted Critical
Publication of ES2325865T3 publication Critical patent/ES2325865T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
ES05773290T 2004-07-26 2005-07-14 Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos. Expired - Lifetime ES2325865T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US59119104P 2004-07-26 2004-07-26
US591191P 2004-07-26

Publications (1)

Publication Number Publication Date
ES2325865T3 true ES2325865T3 (es) 2009-09-22

Family

ID=35134220

Family Applications (1)

Application Number Title Priority Date Filing Date
ES05773290T Expired - Lifetime ES2325865T3 (es) 2004-07-26 2005-07-14 Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos.

Country Status (17)

Country Link
US (1) US7666871B2 (https=)
EP (1) EP1786790B1 (https=)
JP (1) JP4982367B2 (https=)
CN (1) CN1989115B (https=)
AT (1) ATE432926T1 (https=)
AU (1) AU2005275183B2 (https=)
BR (1) BRPI0513777A (https=)
CA (1) CA2575081C (https=)
CY (1) CY1109493T1 (https=)
DE (1) DE602005014786D1 (https=)
DK (1) DK1786790T3 (https=)
ES (1) ES2325865T3 (https=)
MX (1) MX2007001029A (https=)
PL (1) PL1786790T3 (https=)
PT (1) PT1786790E (https=)
SI (1) SI1786790T1 (https=)
WO (1) WO2006019833A1 (https=)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8008301B2 (en) * 2004-04-01 2011-08-30 Eli Lilly And Company Histamine H3 receptor agents, preparation and therapeutic uses
WO2006089076A2 (en) 2005-02-18 2006-08-24 Neurogen Corporation Thiazole amides, imidazole amides and related analogues
CA2602336A1 (en) 2005-03-31 2006-10-05 Ucb Pharma S.A. Compounds comprising an oxazole or thiazole moiety, processes for making them, and their uses
US8637559B2 (en) 2005-11-15 2014-01-28 Otsuka Pharmaceutical Co., Ltd. Oxazole compound and pharmaceutical composition
BRPI0709612A2 (pt) 2006-03-15 2011-07-19 Wyeth Corp composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i
EP2027086B1 (en) 2006-05-19 2011-11-16 Wyeth LLC N-benzoyl-pyrrolidin-3-ylamines as histamine-3 antagonists
US20090215628A1 (en) * 2006-05-19 2009-08-27 Basf Se Benzoyl-Substituted Alanines
US8329159B2 (en) * 2006-08-11 2012-12-11 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
PE20081152A1 (es) 2006-10-06 2008-08-10 Wyeth Corp Azaciclilaminas n-sustituidas como antagonistas de histamina-3
CA2693138A1 (en) * 2007-07-16 2009-01-22 Wyeth Llc Aminoalkylazole derivatives as histamine-3 antagonists
WO2009126782A1 (en) * 2008-04-11 2009-10-15 High Point Pharmaceuticals, Llc Histamine h3 receptor ligands
US8383829B2 (en) * 2008-04-15 2013-02-26 Konica Minolta Holdings, Inc. Electrochromic compound, electrode, and display element
SA110310332B1 (ar) * 2009-05-01 2013-12-10 Astrazeneca Ab مركبات ميثانون (3 استبدال -ازيتيدين -1-يل )(5- فينيل -1، 3، 4- أوكساديازول -2-يل )
SA111320581B1 (ar) 2010-07-06 2014-06-17 استرازينيكا ايه بي مركبات (3-(4-(أمينو ميثيل ) فينوكسي أو فينيل ثيو) أزيتيدين -1- يل) (5- فينيل -1، 3، 4- أوكسا ديازول -2- يل) ميثانون
UY34194A (es) 2011-07-15 2013-02-28 Astrazeneca Ab ?(3-(4-(espiroheterocíclico)metil)fenoxi)azetidin-1-il)(5-(fenil)-1,3,4-oxadiazol-2-il)metanona en el tratamiento de la obesidad?
WO2013151982A1 (en) 2012-04-03 2013-10-10 Arena Pharmaceuticals, Inc. Methods and compounds useful in treating pruritus, and methods for identifying such compounds
MA38287B1 (fr) 2013-01-23 2018-08-31 Astrazeneca Ab Nouveaux dérivés aminopyrazine pour le traitement ou la prévention du cancer
CN107406424B (zh) 2014-12-18 2020-08-25 豪夫迈·罗氏有限公司 雌激素受体调节剂及其用途
WO2016196771A1 (en) 2015-06-03 2016-12-08 Bristol-Myers Squibb Company 4-hydroxy-3-(heteroaryl)pyridine-2-one apj agonists for use in the treatment of cardiovascular disorders
EP3319968A1 (en) 2015-07-06 2018-05-16 Rodin Therapeutics, Inc. Heterobicyclic n-aminophenyl-amides as inhibitors of histone deacetylase
LT3319959T (lt) 2015-07-06 2021-12-27 Alkermes, Inc. Histono deacetilazės hetero-halogeno inhibitoriai
RS62959B1 (sr) 2017-01-11 2022-03-31 Alkermes Inc Biciklični inhibitori histon-deacetilaze
US11225475B2 (en) 2017-08-07 2022-01-18 Alkermes, Inc. Substituted pyridines as inhibitors of histone deacetylase

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3819037A1 (de) * 1988-06-04 1989-12-14 Hoechst Ag 2,4-disubstituierte oxazol-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als therapiemittel gegen krankheiten, die durch rhinoviren verursacht werden
WO1995009159A1 (en) * 1993-09-28 1995-04-06 Otsuka Pharmaceutical Company, Limited Quinoxaline derivative as antidiabetic agent
WO2000064884A1 (en) * 1999-04-26 2000-11-02 Novo Nordisk A/S Piperidyl-imidazole derivatives, their preparations and therapeutic uses
JP2004532834A (ja) 2001-03-23 2004-10-28 イーライ・リリー・アンド・カンパニー ヒスタミンｈ３受容体アンタゴニストである非イミダゾール系アリールアルキルアミン化合物、その製造および治療的使用
AU2003203143B2 (en) 2002-02-01 2009-05-14 High Point Pharmaceuticals, Llc Amides of aminoalkyl-substituted azetidines, pyrrolidines, piperidines and azepanes
US7332508B2 (en) * 2002-12-18 2008-02-19 Novo Nordisk A/S Substituted homopiperidine, piperidine or pyrrolidine derivatives
US7259262B2 (en) * 2003-10-24 2007-08-21 Hoffmann-La Roche Inc. Arylazole derivatives, their manufacture and use as pharmaceutical agents

Also Published As

Publication number Publication date
BRPI0513777A (pt) 2008-05-13
SI1786790T1 (sl) 2009-10-31
US20070197604A1 (en) 2007-08-23
PL1786790T3 (pl) 2009-10-30
DE602005014786D1 (de) 2009-07-16
JP2008507579A (ja) 2008-03-13
PT1786790E (pt) 2009-08-18
DK1786790T3 (da) 2009-07-20
AU2005275183A1 (en) 2006-02-23
CN1989115B (zh) 2012-03-21
CY1109493T1 (el) 2014-08-13
EP1786790A1 (en) 2007-05-23
WO2006019833A1 (en) 2006-02-23
JP4982367B2 (ja) 2012-07-25
US7666871B2 (en) 2010-02-23
AU2005275183B2 (en) 2011-03-17
CN1989115A (zh) 2007-06-27
ATE432926T1 (de) 2009-06-15
MX2007001029A (es) 2007-04-12
CA2575081C (en) 2013-05-07
CA2575081A1 (en) 2006-02-23
EP1786790B1 (en) 2009-06-03

Similar Documents

Publication Publication Date Title
ES2325865T3 (es) Derivados de oxazol como agentes receptores de histamina h3, preparacion y usos terapeuticos.
ES2534605T3 (es) Agentes receptores de la histamina H3, preparación y usos terapéuticos
CN101528717B (zh) 噻唑和*唑-取代的芳基酰胺类化合物
AU2005215918C1 (en) Azabicyclo (3.1.0) hexane derivatives useful as modulators of dopamine D3 receptors
CN101903348B (zh) 吡唑取代的芳基酰胺
BR112013002984B1 (pt) Compostos derivados de triazina e composições farmacêuticas que os compreendem
TW201038586A (en) Sulfonamide derivatives
CN103002897A (zh) 特定氨基-哒嗪类，与其组合物，及其使用方法
ES2923790T3 (es) Piperidinas halosustituidas como moduladores de receptores de orexina
IL285246B2 (en) Substituted bicyclic compounds as farnesoid x receptor modulators
JP2009504791A5 (https=)
BR112021015963A2 (pt) Compostos bicíclicos substituídos como moduladores do receptor de farnesoide x
AU2007284599B2 (en) Oxazolidone derivatives as PR modulators
MXPA06007203A (es) Alfahidroxiamidas como antagonistas o agonistas inversos de bradicinina.
US20140155413A1 (en) TrkA KINASE INHIBITORS, COMPOSITIONS AND METHODS THEREOF
TW200410961A (en) Antimicrobial [3.1.0] bicyclic oxazolidinone derivatives
ES2318565T3 (es) Inhibidores del receptor de la histamina h3, su preparacion y sus usos terapeuticos.
CN112543756A (zh) 用于治疗哺乳动物感染的经取代噁唑烷酮类
JP4966193B2 (ja) Ｄ３受容体に対するアフィニティを有する化合物および医薬におけるその使用
JP2008504332A (ja) ドーパミンｄ３受容体に対してアフィニティーを有する化合物およびその医薬における使用
US20110178140A1 (en) Sulfur containing pyrazole-heterocycle derivatives as cannabinoid cb1 receptor antagonists
BR112017024846B1 (pt) Agonistas de apj de 4-hidróxi-3-(heteroaril)piridina-2- ona, seu uso e composição farmacêutica que os compreende